P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617681/
Olaf-Georg Issinger, Academic Editor Selpercatinib is a targeted, FDA-approved, oral, small-molecule inhibitor for the treatment of rearranged during transfection (RET) proto-oncogene mutation-positive cancer. Using genetically modified mouse models, we investigated...
Conclusions: In summary, ABCG2 and especially ABCB1 can limit the oral exposure and brain and testis penetration of selpercatinib, as well as its intestinal disposition. To the best of our knowledge, this is the first study documenting that elacridar can improve selpercatinib brain accumulation. Additionally, CYP3A-mediated metabolism can...
Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34816395/
1 European University of Cyprus, Engomi-Nicosia, Cyprus. [email protected]. 2 Pharmacoepidemiology-Pharmacovigilance, Pharmacy School, School of Sciences and Engineering, University of Nicosia, Nicosia, Cyprus. 1 European University of Cyprus, Engomi-Nicosia, Cyprus. [email protected]....
Conclusions: Bevacizumab in combination with chemotherapy is cost-effective as neither first-line treatment nor maintenance treatment. Sequential treatment with bevacizumab in first-line and second-line treatment was also not cost-effective. Testing for KRAS and extended RAS mutations is cost-effective and should be performed prior to anti-EGFR...
Identifying potential novel insights for COVID-19 pathogenesis and therapeutics using an integrated bioinformatics analysis of host transcriptome - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34826456/
The molecular mechanisms underlying the pathogenesis of COVID-19 have not been fully discovered. This study aims to decipher potentially hidden parts of the pathogenesis of COVID-19, potential novel drug targets,...
Conclusion/Relevance: We identified drugs currently in clinical trials, others predicted by different methods, and novel potential drug candidates Entrectinib, Omeprazole, and Exemestane for combating COVID-19.
Metformin inhibits human non-small cell lung cancer by regulating AMPK-CEBPB-PDL1 signaling pathway - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34837101/
Metformin has been found to have inhibitory effects on a variety of tumors. However, its effects on non-small cell lung cancer (NSCLC) remain unclear. We demonstrated that metformin could inhibit...
Conclusion/Relevance: In conclusion, metformin inhibited the proliferation of NSCLC cells and played an anti-tumor role in an AMPK-CEBPB-PDL1 signaling-dependent manner.
Circular RNA circ_0000517 Facilitates The Growth and Metastasis of Non-Small Cell Lung Cancer by Sponging miR-326/miR-330-5p - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34837683/
Objective: There is growing evidence showing that circular RNAs (circRNAs) are crucial regulators in modulating the biological behavior of tumors. This work is aimed to probe the role of circ_0000517...
Conclusion/Relevance: This work reveals that circ_0000517 is implicated in NSCLC cell growth and metastasis through the modulation of miR-326/miR-330-5p/MMP2, providing novel insights into the role of circRNAs in NSCLC progression.